Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.

MLA

Gil, Kellen B., et al. “Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine and Venetoclax in Acute Myeloid Leukemia.” Leukemia & Lymphoma, Sept. 2024, pp. 1–3. EBSCOhost, https://doi.org/10.1080/10428194.2024.2397570.

APA

Gil, K. B., Abbott, D., Amaya, M. L., Schwartz, M., Gutman, J. A., Kent, A., Bosma, G., Pollyea, D. A., & McMahon, C. M. (2024). Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leukemia & Lymphoma, 1–3. https://doi.org/10.1080/10428194.2024.2397570

Chicago

Gil, Kellen B, Diana Abbott, Maria L Amaya, Marc Schwartz, Jonathan A Gutman, Andrew Kent, Grace Bosma, Daniel A Pollyea, and Christine M McMahon. 2024. “Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine and Venetoclax in Acute Myeloid Leukemia.” Leukemia & Lymphoma, September, 1–3. doi:10.1080/10428194.2024.2397570.